Immunotech Biopharm Ltd (6978.HK)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Zheng Tan | Executive Chairman | 5.05M | -- | 1978 |
| Dr. Yu Wang | CEO, Co-Chief Technology Officer & Executive Director | 4.86M | -- | 1969 |
| Mr. Hyun Chul Jung | Founder & Chief Strategy Officer | 1.98M | -- | 1964 |
| Mr. Ning Yang | CFO & Company Secretary | -- | -- | 1982 |
| Dr. Yu Zhang | Chief Scientist | -- | -- | 1964 |
| Dr. Hyun-Soo Lee | Co-Chief Technology Officer | -- | -- | -- |
| Mr. Jian Zhang | Senior Vice President | -- | -- | 1971 |
Immunotech Biopharm Ltd
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 211
Description
Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People's Republic of China. Its core product is EAL, a multi-target cellular immunotherapy product that is in Phase II clinical trials for the prevention of postsurgical recurrence of liver cancer. The company is also conducting pre-clinical and clinical trial studies for EAL to treat lung cancer, glioma, gastric cancer, and colorectal cancer. In addition, it develops 6B11-OCIK injection that is in Phase I clinical trial for ovarian cancer; CAR-T-19 injection product for B-cell acute lymphoblastic leukaemia; RC19D2 for non-hodgkin lymphoma; and TCR-T cell series products to treat solid tumors. Further, the company's pre-clinical products include aT19 to treat acute lymphoblastic leukaemia; CAR-T-43 for T cell leukaemia and T cell lymphoma; CAR-T-22 for B lymphocyte leukaemia; CAR-T-BCMA to treat multiple myeloma; CAR-T-ENX for solid tumors; TCR800 to treat renal cancer; and EBV, CMV specific T cells for EBV/CMV infection. Immunotech Biopharm Ltd was founded in 2006 and is headquartered in Beijing, the People's Republic of China.
Corporate Governance
Recent Events
Recent Events Information Not Available